Fig. 3
From: Outcome of a single XEN microstent implant for glaucoma patients with different types of glaucoma
IOP-lowering agents over study time. Progression of the number of mean IOP-lowering agents (number) used in the entire XEN Microstent patient group and in the subgroups depending on glaucoma type during the first 12 months of postoperative follow-up. (primary open angle glaucoma (POAG); normal pressure glaucoma (NTG); pseudoexfoliation glaucoma (PEX); secondary glaucoma (sec. Gl))